Among the therapeutic strategies aimed to target individual molecules associated with IGF-1R network, PI3K inhibitors are classified as valuable candidates.96 Clinical trials evaluating combinations of PI3K inhibitors and hormonal therapy (NCT01296555, NCT01870505) or other anti-cancer agents (NCT02051751, NCT01822613) are underway against breast cancer. This evidence concerns the gene IGF1R and breast carcinoma.